Literature DB >> 15780091

Positive correlation between sialyl Lewis X expression and pathologic findings in renal cell carcinoma.

Keiichi Tozawa1, Takashi Okamoto, Noriyasu Kawai, Yoshihiro Hashimoto, Yutaro Hayashi, Kenjiro Kohri.   

Abstract

BACKGROUND: Interaction between tumor cells and endothelium plays a major role in cancer invasion and metastasis. Among various cell adhesion molecules, the cognate interaction between sialyl Lewis antigen expressed in the tumor cell surface and E-selectin expressed on endothelial cells is considered to be crucial for the tumor cell adhesion to the endothelium.
METHODS: The sialyl Lewis X (sL(X)) expression in 45 specimens from renal cell carcinoma patients was examined using immunohistochemistry.
RESULTS: In this study, we demonstrate that the immunoreactivity for sL(X) in renal cell carcinoma specimens not only correlates with conventional histopathologic parameters but also serves as a useful indicator for the prognosis of renal cell carcinoma.
CONCLUSION: Since beneficial effect of cimetidine has been reported and ascribed to its inhibitory action on the expression of E-selectin, a ligand molecule of sialyl Lewis antigen, cimetidine may also show inhibitory effect on the tumor recurrence and metastasis of renal cell carcinoma with high level of sL(X) expression.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15780091     DOI: 10.1111/j.1523-1755.2005.00216.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

1.  Blood group antigens SLeX, SLeA, and LeY as prognostic markers in endometrial cancer.

Authors:  Thomas Kolben; Lena Müller; Sarah Meister; Lucia Keilmann; Christina Buschmann; Fabian Trillsch; Alexander Burges; Bastian Czogalla; Sophie Mitter; Elisa Schmoeckel; Stefanie Corradini; Sven Mahner; Udo Jeschke; Mirjana Kessler; Susanne Beyer
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-21       Impact factor: 4.322

Review 2.  Prognostic and Therapeutic Role of CD15 and CD15s in Cancer.

Authors:  Wojciech Szlasa; Karol Wilk; Klaudia Knecht-Gurwin; Adam Gurwin; Anita Froń; Natalia Sauer; Wojciech Krajewski; Jolanta Saczko; Tomasz Szydełko; Julita Kulbacka; Bartosz Małkiewicz
Journal:  Cancers (Basel)       Date:  2022-04-28       Impact factor: 6.575

3.  Sialyl Lewis x expression in cervical scrapes of premalignant lesions.

Authors:  Noé Velázquez-Márquez; Gerardo Santos-López; Lucio Jiménez-Aranda; Julio Reyes-Leyva; Verónica Vallejo-Ruiz
Journal:  J Biosci       Date:  2012-12       Impact factor: 1.826

4.  Expression of hypoxia-inducible protein 2 in renal cell carcinoma: A promising candidate for molecular targeting therapy.

Authors:  Takashi Seo; Ryuichiro Konda; Jun Sugimura; Kazuhiro Iwasaki; Yusuke Nakamura; Tomoaki Fujioka
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

Review 5.  Specificity in cancer immunotherapy.

Authors:  Andrea Schietinger; Mary Philip; Hans Schreiber
Journal:  Semin Immunol       Date:  2008-08-05       Impact factor: 11.130

Review 6.  Targeting Selectins and Their Ligands in Cancer.

Authors:  Alessandro Natoni; Matthew S Macauley; Michael E O'Dwyer
Journal:  Front Oncol       Date:  2016-04-18       Impact factor: 6.244

7.  Distinguishing Benign and Malignant Thyroid Nodules and Identifying Lymph Node Metastasis in Papillary Thyroid Cancer by Plasma N-Glycomics.

Authors:  Zejian Zhang; Karli R Reiding; Jianqiang Wu; Zepeng Li; Xiequn Xu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-06-25       Impact factor: 5.555

8.  CD44v4 is a major E-selectin ligand that mediates breast cancer cell transendothelial migration.

Authors:  Ke Zen; Dan-Qing Liu; Ya-Lan Guo; Chen Wang; Jun Shan; Ming Fang; Chen-Yu Zhang; Yuan Liu
Journal:  PLoS One       Date:  2008-03-19       Impact factor: 3.240

Review 9.  Altered tumor-cell glycosylation promotes metastasis.

Authors:  Irina Häuselmann; Lubor Borsig
Journal:  Front Oncol       Date:  2014-02-13       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.